CIRM just helped reach a major milestone in treating myelodysplastic syndromes (MDS), a rare disorder that affects red blood cell production.
Positive early results
Jasper Therapeutics announced new data from their Phase 1 clinical trial treating people with MDS. This group of disorders involves abnormal, immature blood‑forming cells in the bone marrow, leading to low levels of healthy blood cells—especially red blood cells. In about one‑third of patients, MDS progresses to acute myeloid leukemia, a fast‑growing bone marrow cancer.
The most effective treatment—sometimes even a cure—is a blood stem cell transplant. But this approach is difficult for older patients because it requires toxic chemotherapy to destroy existing bone marrow stem cells and make room for healthy donor cells. Even then, relapse rates remain high because chemotherapy often cannot eliminate all cancer cells.
Monoclonal antibody
Jasper has developed a monoclonal antibody therapy, JSP191, to address this challenge. JSP191 helps clear remaining abnormal cells from the bone marrow and reduces relapse risk. It also allows patients to receive lower‑toxicity chemotherapy.
In this Phase 1 study, six patients aged 65 to 74 received JSP191 with low‑dose radiation and chemotherapy before their transplant. At 90 days, five patients had no detectable MDS/AML, and the sixth showed reduced levels. None experienced serious side effects.
Clearly, that’s encouraging news. And while CIRM didn’t fund this clinical trial, it wouldn’t have happened without CIRM paving the way for this research.
CIRM support helped develop the JSP191 technology at Stanford. Our CIRM funds supported the preclinical studies that form the scientific basis for using JSP191 in an MDS/AML setting.
Not only that, but this same technique was also used by Stanford’s Dr. Judy Shizuru in a clinical trial for children born with a form of severe combined immunodeficiency, a rare but fatal immune disorder in children. A clinical trial that CIRM funded.
It’s a reminder that therapies developed for one condition can often be adapted to treat similar conditions. Jasper is doing just that. It hopes to start clinical trials this year using JSP191 for people getting blood stem cell transplants for severe autoimmune disease, sickle cell disease, and Fanconi anemia.
